Acute myeloid leukemia’s minimal residual disease targeted by Moon Shot
In patients with leukemia, complete remission after treatment is currently defined by the absence of cancer cells in a bone marrow biopsy viewed under the microscope. However, it’s well-established that if no further treatment is given, some patients will relapse due to undetectable cancer cells remaining in the body. This small number of remaining cells is known as minimal residual disease (MRD).
Ghayas Issa, M.D., assistant...
Ovarian Cancer Moon Shot works to broaden immunotherapy impact
Immunotherapies have brought the potential for long-term remission and even cures to patients with many cancer types, but the benefits have...
Making CAR T cell therapy more effective for B-cell lymphoma treatment
Chimeric antigen receptor (CAR) T cells were approved by the Food and Drug Administration (FDA) to treat relapsed and refractory large B-cell...
MD Anderson accelerates cellular therapy programs by buying state-of-art manufacturing facility
Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an important role in advancing these novel treatments to the clinic. With recent agreements, MD Anderson has expanded its manufacturing and research capacity for cell therapies to bring new treatment options to more patients.
This month, MD Anderson finalized an asset purchase agreement with Bellicum...
ECLIPSE looks to extinguish leukemia by uncovering new treatment targets
MD Anderson has created a new research platform to drive the discovery of new therapeutic agents for patients with leukemia by investigating...
Metastatic cells, mechanisms of drug resistance identified for triple-negative breast cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in...
Immunotherapy innovation: Moon Shots effort aims natural killer cells at cancer
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches...
Moon Shot promotes efforts to prevent, quickly detect pancreatic cancer
Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type...
APOLLO’s high-quality longitudinal samples empower cancer investigators
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...
Moon Shot rises to challenge of glioblastoma
Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...